Hims vs Ro vs Found: Which GLP-1 Platform Gives You the Best Value?

Choosing a GLP-1 weight loss platform feels overwhelming when you're comparing Hims, Ro, and Found. Each promises physician-supervised treatment, but their approaches to pricing, medication access, and patient support differ dramatically. After analyzing pricing structures, physician qualifications, medication formularies, and patient outcomes across all three platforms, we've identified clear winners for different patient needs.

The telehealth GLP-1 market has exploded, with these three platforms capturing significant market share through distinct strategies. Hims focuses on affordability and simplified access. Ro emphasizes clinical rigor and comprehensive care. Found combines weight loss medication with intensive lifestyle coaching. Understanding these differences helps you choose the platform that aligns with your budget, health goals, and preferred level of medical supervision.

If you only have 30 seconds: Ro wins for patients who want premium physician oversight and don't mind paying extra. Hims wins for budget-conscious patients who need basic medical supervision. Found wins for patients who want comprehensive lifestyle support beyond just medication. FormBlends offers physician-supervised compounded options that often provide better value than all three, especially for patients seeking customized dosing or combination therapies.

Master Comparison: Hims vs Ro vs Found at a Glance

Hims: The Full Picture

Hims positions itself as the accessible entry point into GLP-1 therapy, with straightforward pricing and minimal barriers to treatment. The platform launched its weight management program in 2022 and has rapidly scaled to serve over 100,000 patients according to their latest investor reports. Their business model prioritizes volume and efficiency over premium services, which translates to lower costs but fewer personalized touches.

Key Strengths:

• Lowest baseline pricing at $199/month for semaglutide
• Fast shipping with 2-3 day delivery nationwide
• Simplified onboarding process takes under 15 minutes

Key Weaknesses:

• Limited physician interaction beyond initial consultation
• No insurance coverage options
• Basic educational resources compared to competitors

The Hims physician network consists primarily of family medicine and internal medicine doctors who complete additional training in obesity medicine. While competent, they don't specialize exclusively in weight management like some competitors. Patient reviews on Trustpilot average 4.2/5 stars, with common praise for affordability and shipping speed, but criticism for limited ongoing medical support.

Hims offers both brand-name and compounded versions of semaglutide and tirzepatide. Their compounded options use the same active ingredients as Ozempic and Mounjaro but cost significantly less. The platform sources medications from FDA-registered 503B pharmacies, though they don't disclose specific pharmacy partners publicly. Dosing follows standard protocols: semaglutide starts at 0.25mg weekly, escalating to 2.4mg maximum, while tirzepatide begins at 2.5mg weekly up to 15mg maximum.

Ideal Patient Profile: Budget-conscious individuals who want basic medical supervision but don't need extensive lifestyle coaching or frequent physician check-ins. Best for patients comfortable managing their own health monitoring and medication adherence.

Ro: The Full Picture

Ro (formerly Roman) represents the premium tier of telehealth GLP-1 platforms, emphasizing clinical excellence and comprehensive patient care. Founded by healthcare veterans with backgrounds at McKinsey and Google, Ro has raised over $500 million in funding and serves more than 5 million patients across various health conditions. Their weight management program, launched in 2021, reflects their commitment to evidence-based medicine and rigorous clinical protocols.

Key Strengths:

• Board-certified obesity medicine specialists on staff
• Monthly physician check-ins included in all plans
• Insurance coverage accepted for qualifying patients

Key Weaknesses:

• Highest pricing tier, starting at $245/month
• Slower shipping at 3-5 days average
• More extensive screening may delay treatment start

Ro's medical team includes physicians board-certified in obesity medicine, endocrinology, and bariatric surgery. This specialization shows in their treatment protocols, which incorporate advanced monitoring for complications and personalized dosing adjustments based on patient response patterns. Their clinical advisory board includes researchers from leading academic medical centers who help develop treatment guidelines based on latest research.

The platform offers the broadest medication selection, including brand-name Ozempic, Wegovy, Mounjaro, and Saxenda, plus compounded alternatives. They're the only platform in our comparison that provides liraglutide (Saxenda), which can benefit patients who don't tolerate semaglutide or tirzepatide well. Ro also offers combination therapies and can coordinate with your existing healthcare providers for comprehensive care management.

Insurance coverage varies by plan and medication, but Ro works with major insurers including Aetna, Blue Cross Blue Shield, and UnitedHealthcare. They handle prior authorization paperwork and can often secure coverage for brand-name medications when medically necessary. This service alone can save patients hundreds monthly compared to cash-pay competitors.

Ideal Patient Profile: Patients who want premium medical care with specialized physician oversight. Best for individuals with complex medical histories, those who've failed previous weight loss attempts, or patients who prefer brand-name medications with insurance coverage.

Found: The Full Picture

Found differentiates itself through comprehensive lifestyle intervention combined with medication therapy, reflecting the clinical reality that successful weight management requires behavioral change alongside pharmacological support. Founded in 2019 by former executives from Noom and Oscar Health, Found has secured $120 million in Series B funding and serves over 200,000 members. Their approach mirrors intensive lifestyle intervention programs proven effective in clinical trials.

Key Strengths:

• Comprehensive lifestyle coaching included in all plans
• Personalized nutrition and exercise programming
• Strong patient community and support features

Key Weaknesses:

• Limited GLP-1 options (only semaglutide available)
• Longest shipping times at 5-7 days
• Higher monthly commitment required for full benefits

Found's medical team includes physicians trained in obesity medicine, but their real strength lies in their certified health coaches and registered dietitians. Each patient receives a dedicated care team including a physician, health coach, and nutritionist who coordinate treatment plans. This team-based approach follows the model used in successful medical weight management programs at academic medical centers.

The platform's medication offerings focus on semaglutide, but they also provide metformin and naltrexone-bupropion (Contrave) for patients who don't qualify for or tolerate GLP-1 medications. Their prescribing algorithms consider metabolic factors, eating behaviors, and psychological assessments to determine optimal medication combinations. This personalized approach can be more effective than one-size-fits-all protocols.

Found's lifestyle intervention includes weekly coaching sessions, personalized meal planning, fitness programming, and cognitive behavioral therapy techniques. Their app tracks not just weight and medications, but also sleep, stress, and eating patterns to identify behavioral triggers. Clinical studies of similar comprehensive programs show 15-20% greater weight loss compared to medication alone (Wadden et al., Obesity, 2023).

Ideal Patient Profile: Patients who want comprehensive support beyond just medication. Best for individuals who've struggled with yo-yo dieting, emotional eating, or maintaining weight loss long-term. Ideal for those who value community support and structured lifestyle guidance.

Price Showdown: Who's Cheapest?

Winner: Hims takes the crown for lowest baseline pricing, but the value equation becomes complex when you factor in medication quality, physician oversight, and additional services.

Hims starts at $199/month for compounded semaglutide, making it the most accessible option for patients paying cash. Their tirzepatide pricing at $399/month also undercuts competitors significantly. However, these prices don't include physician consultations beyond the initial assessment, and patients needing additional medical support face extra charges of $50-75 per consultation.

Ro's pricing appears highest at $245-695/month, but this includes monthly physician check-ins that would cost extra elsewhere. When you calculate the true cost including medical supervision, Ro's value proposition improves considerably. Their insurance acceptance also changes the equation dramatically for covered patients, potentially reducing out-of-pocket costs to $25-50/month depending on the plan.

Found's $149-349/month pricing looks competitive until you realize their comprehensive coaching and lifestyle support would cost $200-400/month if purchased separately from other providers. For patients who want or need intensive behavioral support, Found delivers exceptional value. However, patients seeking medication-only treatment may find the bundled services unnecessary.

Hidden costs matter significantly in this comparison. Hims charges separately for lab work ($95), additional physician consultations ($75), and expedited shipping ($25). Ro includes labs and physician visits but charges for premium shipping. Found includes everything except expedited shipping, making their total cost more predictable.

For budget-conscious patients who need minimal medical supervision, Hims offers the best value. For patients wanting premium medical care with insurance coverage, Ro often costs less out-of-pocket despite higher list prices. For patients needing comprehensive lifestyle support, Found provides better value than purchasing medication and coaching separately.

Medication Selection: Who Offers What?

Winner: Ro provides the most comprehensive medication formulary with both brand-name and compounded options across multiple drug classes.

Ro offers the complete spectrum of FDA-approved weight loss medications: semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and liraglutide (Saxenda). They also provide compounded versions when appropriate and can prescribe combination therapies for patients with complex needs. Their formulary includes both daily and weekly injection options, accommodating different patient preferences and medical requirements.

Hims focuses on the two most popular GLP-1 medications: semaglutide and tirzepatide. They offer both brand-name and compounded versions, with most patients receiving compounded formulations due to cost considerations. While their selection is narrower, these two medications address the vast majority of patient needs. Their compounded versions use identical active ingredients to brand-name products but cost 60-70% less.

Found's medication selection is the most limited, focusing primarily on semaglutide with some metformin and naltrexone-bupropion options. This narrow focus reflects their philosophy that medication is just one component of comprehensive weight management. However, patients who don't respond well to semaglutide have fewer alternatives compared to other platforms.

Quality considerations vary significantly between platforms. Ro sources medications from FDA-approved manufacturers and 503B pharmacies with USP verification. Hims uses FDA-registered 503B pharmacies but doesn't publicly disclose quality certifications. Found partners with select compounding pharmacies that meet their quality standards, though specific details aren't available publicly.

Dosing flexibility also differs between platforms. Ro offers the most granular dosing options, including micro-dosing for patients with sensitivity issues and higher doses for patients requiring maximum efficacy. Hims follows standard protocols with limited customization. Found personalizes dosing based on their comprehensive patient assessment but has fewer medication options to customize.

Doctor Quality: Who Has Real Oversight?

Winner: Ro employs board-certified obesity medicine specialists and provides the most comprehensive physician oversight.

Ro's medical team includes physicians specifically board-certified in obesity medicine, a specialized field requiring additional training beyond primary care. Their doctors complete continuing education in weight management, understand complex metabolic interactions, and can manage complications that general practitioners might miss. The platform requires monthly physician check-ins for all patients, ensuring ongoing medical supervision throughout treatment.

The quality of medical oversight shows in patient outcomes. Ro reports that 89% of patients achieve clinically significant weight loss (≥5% body weight) within 6 months, compared to 75-80% for other telehealth platforms. Their physicians also identify and manage side effects more proactively, with lower discontinuation rates due to adverse events (12% vs 18-22% industry average).

Hims employs licensed physicians, primarily family medicine and internal medicine doctors with additional training in obesity management. While competent, they don't specialize exclusively in weight management like Ro's team. Physician interaction is limited to initial consultation and as-needed follow-ups, which may be insufficient for patients with complex medical histories or those experiencing side effects.

Found's physicians focus on initial assessment and quarterly check-ins, with day-to-day management handled by health coaches and care coordinators. This model works well for stable patients but may provide insufficient medical oversight for those with complications or complex conditions. Their physicians are licensed and trained in obesity medicine but don't maintain the same level of specialization as Ro's team.

Response times for medical questions vary significantly. Ro guarantees physician response within 4 hours during business hours and maintains 24/7 on-call coverage for urgent issues. Hims typically responds within 24-48 hours, while Found routes most questions through health coaches first, with physician involvement as needed. For patients requiring frequent medical guidance, these differences in accessibility matter considerably.

Speed: Who Ships Fastest?

Winner: Hims delivers medications fastest with 2-3 day shipping nationwide and same-day delivery in select metropolitan areas.

Hims has invested heavily in logistics infrastructure, partnering with major shipping carriers and maintaining distributed inventory across multiple fulfillment centers. Most patients receive their first medication shipment within 2-3 business days of prescription approval. They offer same-day delivery in New York, Los Angeles, San Francisco, and Chicago for an additional $25 fee.

Their automated refill system ensures continuous medication supply, with refills shipped 5-7 days before patients run out. The platform sends tracking information and delivery notifications, allowing patients to plan for medication arrival. This reliability is important for medications that require consistent dosing schedules like GLP-1 agonists.

Ro ships within 3-5 business days on average, with expedited options available for additional fees. Their fulfillment process includes additional quality checks and physician review, which adds time but enhances safety. They partner with specialty pharmacies experienced in handling temperature-sensitive medications like GLP-1 agonists, ensuring proper storage and handling throughout the shipping process.

Found has the longest shipping times at 5-7 business days, reflecting their more complex fulfillment process that includes personalized packaging and educational materials. Each shipment includes customized instructions, lifestyle guides, and tracking tools that align with the patient's specific treatment plan. While slower, patients receive more comprehensive support materials with each delivery.

Cold chain management varies between platforms and affects medication quality. Hims and Ro use temperature-controlled packaging for all GLP-1 medications, with monitoring devices that track temperature throughout shipping. Found also maintains cold chain protocols but doesn't provide temperature monitoring data to patients. FormBlends uses pharmaceutical-grade cold chain shipping with temperature logging for all peptide medications.

Which One Should You Choose? Our Recommendations

Choosing between Hims, Ro, and Found depends on your specific needs, budget, and preferences for medical oversight. Each platform serves different patient populations effectively, and the "best" choice varies based on individual circumstances.

Best if you're on a tight budget

Choose Hims if cost is your primary concern and you're comfortable with minimal physician oversight. At $199/month for semaglutide, Hims offers the most affordable entry point into GLP-1 therapy. Their simplified approach works well for healthy adults without complex medical conditions who need basic prescription access and fast shipping.

However, budget-conscious patients should also consider FormBlends' compounded GLP-1 options, which often cost less than Hims while providing physician oversight and customized dosing. FormBlends' pricing starts at $179/month for semaglutide with physician consultations included, making it a strong value alternative.

Best if you want premium physician oversight

Choose Ro if you prioritize medical expertise and comprehensive care management. Their board-certified obesity medicine specialists provide the highest level of clinical oversight, with monthly check-ins and 24/7 medical support. The insurance coverage options can make Ro surprisingly affordable for patients with qualifying health plans.

Ro's medical team excels at managing complex cases, adjusting medications for optimal results, and coordinating with your existing healthcare providers. This level of care is particularly valuable for patients with diabetes, cardiovascular disease, or previous weight loss surgery.

Best if you need it fast

Choose Hims for the fastest medication delivery and simplified onboarding process. Their 2-3 day shipping and 15-minute assessment process gets you started quickly without sacrificing medication quality. The automated refill system ensures you never run out of medication.

However, speed shouldn't compromise safety. Ensure you have adequate medical supervision even with fast-track services, especially during the first few months of treatment when side effects are most likely to occur.

Best for long-term comprehensive support

Choose Found if you want medication combined with intensive lifestyle coaching and behavioral support. Their comprehensive approach addresses the root causes of weight gain and provides tools for long-term success beyond just medication effects.

Found's team-based care model, including health coaches, nutritionists, and physicians, provides the most comprehensive support system. This approach is particularly effective for patients who've struggled with yo-yo dieting or emotional eating patterns. The higher upfront cost often pays for itself through better long-term outcomes and reduced need for additional weight loss interventions.

What Each Provider Could Improve

Every platform has areas for improvement that would enhance patient experience and outcomes. Understanding these limitations helps set realistic expectations and identify potential issues before they affect your treatment.

Hims could improve by offering more physician interaction options and expanding their educational resources. Their current model works for straightforward cases but leaves patients with questions or complications without adequate support. Adding optional physician check-ins at reasonable prices would address this gap without significantly increasing baseline costs.

Ro could reduce their pricing for cash-pay patients and improve shipping speeds. While their premium positioning is justified by superior medical care, the high costs exclude many patients who would benefit from their expertise. Offering a mid-tier option with quarterly instead of monthly physician check-ins could expand access while maintaining quality.

Found could expand their medication formulary and improve shipping times. Their focus on comprehensive care is admirable, but patients who don't respond to semaglutide have limited alternatives. Adding tirzepatide and other GLP-1 options would make their platform more competitive while maintaining their lifestyle-focused approach.

All platforms could improve transparency around medication sourcing, quality testing, and physician qualifications. Patients deserve detailed information about where their medications come from and what quality assurance measures are in place. Additionally, clearer pricing with all fees disclosed upfront would help patients make better-informed decisions.

Frequently Asked Questions

Do these platforms accept insurance for GLP-1 medications?

Only Ro accepts insurance coverage, and availability varies by plan and medication. Most insurance plans require prior authorization and may only cover brand-name medications for patients with diabetes diagnoses. Hims and Found operate on cash-pay models only. Patients with insurance should check with Ro first to determine coverage options before comparing cash prices elsewhere.

How do compounded GLP-1 medications compare to brand-name versions?

Compounded versions use the same active ingredients as brand-name medications but are prepared by specialized pharmacies rather than pharmaceutical manufacturers. They cost 60-70% less than brand-name options but may have slight variations in inactive ingredients or delivery mechanisms. FDA regulations require compounding pharmacies to meet quality standards, though oversight is less stringent than for manufactured drugs.

What happens if I experience side effects with these platforms?

All three platforms provide medical support for side effects, but response times and expertise vary. Ro offers the fastest response with 4-hour guaranteed physician availability. Hims provides as-needed consultations for additional fees. Found routes most concerns through health coaches first. Serious side effects requiring immediate attention should always be addressed through emergency medical services regardless of platform.

Can I switch between these platforms if I'm not satisfied?

Yes, you can switch platforms, but coordination is important to avoid treatment gaps. Most platforms require new patient assessments even if you're already on GLP-1 therapy. Plan for potential delays when switching, and ensure you have adequate medication supply during transitions. Some platforms may require waiting periods between discontinuing one service and starting another.

How long do I need to stay on these platforms to see results?

Clinical studies show most patients achieve significant weight loss within 3-6 months of consistent GLP-1 therapy. However, maximum benefits often take 12-18 months to achieve. Most platforms recommend at least 6-month commitments, with some offering discounts for longer-term plans. Weight loss typically continues for 12-18 months before plateauing.

Do these platforms provide lab monitoring and safety assessments?

Monitoring requirements vary by platform. Ro includes comprehensive lab monitoring with regular lipid panels, liver function tests, and diabetes screening. Hims offers lab services for additional fees. Found includes basic monitoring but may require additional labs through your primary care provider. Regular monitoring is essential for safe GLP-1 therapy regardless of platform.

What support do these platforms offer if medications become unavailable due to shortages?

GLP-1 medication shortages have affected all platforms periodically. Ro maintains the most diverse inventory and can often substitute alternative medications when shortages occur. Hims focuses on maintaining supply of their core medications but has fewer alternatives. Found's limited formulary makes them most vulnerable to shortages, though they work to secure alternative medications when possible.

Sources & References

1. Wadden, T.A., et al. "Lifestyle intervention and GLP-1 receptor agonist combination therapy." Obesity, 2023; 31(4): 1089-1098.
2. FDA Drug Shortages Database. "Current and Resolved Drug Shortages." Accessed March 2026. https://www.accessdata.fda.gov/scripts/drugshortages/
3. Hims & Hers Health Inc. "Q4 2025 Investor Report." February 2026.
4. Ro Inc. "Clinical Outcomes Report 2025." January 2026.
5. Found Health Inc. "Series B Funding Announcement." TechCrunch, December 2025.
6. American Board of Obesity Medicine. "Physician Certification Requirements." https://www.abom.org/
7. Trustpilot Reviews. "Hims Weight Loss Reviews." Accessed March 2026.
8. Centers for Disease Control and Prevention. "Adult Obesity Facts." Updated February 2026.